Table 1(B).

The summary of patients with concomitant NTM infection and malignant lymphoma.

	Case 5 (Brousset et al., 1994)	Case 6 (Kenali et al., 2004)	Case 7 (Yaxsier et al., 2011)	Case 8 (Gupta et al., 2011)
Age/sex	27/M	31/M	13/F	5/M
Phenotype of lymphoma	EBV-associated HL (MC type)	NHL (unknown phenotype)	HL (MC type)	NLPHL
Mycobacterium species	MAC	Not identified	M. avium	MAC
Clinical presentation	Intermittent fever, lymphadenopathy	Right facial swelling	Supraclavicular mass	Cervical lymphadenopathy
Other underlying conditions	AIDS	AIDS	None	None
Immunosuppressants	None	None	None	None
CD4 positive T cell count	<50	N/A	N/A	N/A
Biopsy sites of lymph node	Left cervical LN	Intranasal ulcerating lesion	Supraclavicular LN	Lung, left supraclavicular LN
Infection sites of Mycobacterium	Left cervical LN	Intranasal ulcerating lesion	Supraclavicular LN	Lung, gastric aspirates
Treatment of mycobacterium	N/A	EB, RFP, INH, PZA	EB, RFP, AZM	EB, RFP, AZM
Treatment of lymphoma	N/A	None	VCR, ADR, ETP	ABVE/PC
Outcome	Die of the perforated intestine	Die before starting treatment	CR	CR

ABVD, adriamycin, bleomycin, vinblastine and dacarbazine; ABVE/PC, adriamycin, bleomycin, vincristine, etoposide, prednisone and cyclophosphamide; ADR, adriamycin; AIDS, acquired immune deficiency syndrome; AZM, aztreonam; CAM, clarithromycin; CR, complete remission; EB, ethambutol; ETP, etoposide; HL, Hodgkin’s lymphoma; INH, isoniazid; MC, mixed cellularity; NLPHL, nodular lymphocyte predominant Hodgkin lymphoma; MAC, mycobacterium avium complex; N/A, not available; PZA, pyrazinamide; RFP, rifampicin; VCR, vincristine